HuMOLYTE Study Submitted for Peer Review
Chemotherapy-induced mucositis is one of the most painful and debilitating side effects experienced by cancer patients, often leading to severe diarrhea, dehydration, electrolyte imbalances, and difficulty maintaining adequate nutrition. In a newly submitted study currently under peer review, researchers investigated whether Humolyte®, a medical food containing 2’-fucosyllactose (2’-FL)—a beneficial prebiotic originally identified in human milk—combined with magnesium and electrolytes, could reduce gastrointestinal and oral mucosal injury caused by commonly used chemotherapy agents. Using a Wistar rat model, the study demonstrated that Humolyte® supplementation significantly reduced diarrhea severity, preserved intestinal and oral tissue structure, improved epithelial barrier function, increased mucin production, and reduced chemotherapy-related weight loss. These findings suggest that Humolyte® may offer a promising supportive care strategy to help protect the gut and oral lining during cancer treatment. Below is the full text of the study.
For more information on how HuMOLYTE can support your gut health during chemotherapy, visit our product page or consult your health care provider.
This blog was reviewed by Dr. Sourabh Kharait.
This blog is for educational purposes only and is not intended as medical advice. Always consult with your healthcare provider before making any changes to your treatment plan, hydration strategies, or diet. The information provided here is based on general insights and may not apply to individual circumstances.
